A STUDY TO EVALUATE THE EFFICACY OF DIFFERENT DOSES OF CHANNA STRIATUS EXTRACT AMONG PRIMARY KNEE OSTEOARTHRITIS PATIENTS

A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY OF DIFFERENT DOSES OF ORAL CHANNA STRIATUS EXTRACT AMONG PRIMARY KNEE OSTEOARTHRITIS PATIENTS

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20170513004

Enrollment

Unknown

Registered

2017-05-13

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Knee Osteoarthritis osteoarthritis arthritis

Interventions

Oral Channa striatus extract 1000mg/day,Oral Channa striatus extract 500mg/day,placebo 500mg (corn starch)

Active Comparator Dietary Supplement,Active Comparator Dietary Supplement,Placebo Comparator Dietary Supplement

channa striatus 1000mg/day,Channa striatus 500mg/day,placebo

Eligibility

Sex/Gender

All

Age

40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients with unilateral or bilateral knee osteoarthritis according to clinical and radiological criteria of the American College of Rheumatology (ACR). 2.Have a radiological grade between I and III, as measured with the Kellgren-Lawrence method of Classification.

Exclusion criteria

Exclusion criteria: 1-Patient with secondary knee osteoarthritis, such as post traumatic OA, inflammatory arthritis, specifically rheumatoid arthritis, active gout 2-Disabling co-morbid condition such as renal disease, liver disease, neoplasm, and other rheumatic diseases. 3-Pregnancy or nursing. 4-Patient with severe knee pain and willing for surgical intervention. 5-Those who had joint lavage, arthroscopy, or treatment with hyaluronic acid, or glucosamine during the previous 6 months. 6-Patient who had been treated with intra-articular corticosteroids during the past 3 months. 7-Patient who have allergic to oral C.striatus

Design outcomes

Primary

Measure	Time frame
Pain domain of Western Ontario and McMaster University Osteoarthritis Index changes from baseline to 6 months visual analogue score (VAS)	—

Secondary

Measure	Time frame
Functional domain of Western Ontario and McMaster University Osteoarthritis Index changes from baseline to 6 months visual analogue score (VAS),stiffness domain of Western Ontario and McMaster University Osteoarthritis Index changes from baseline to 6 months visual analogue score (VAS),analgesic score mean score at month 6 numericla score,serum Cartilage Oligomeric Matric Protein. changes from baseline to 6 months ng/ml	—

Measure

Time frame

Functional domain of Western Ontario and McMaster University Osteoarthritis Index changes from baseline to 6 months visual analogue score (VAS),stiffness domain of Western Ontario and McMaster University Osteoarthritis Index changes from baseline to 6 months visual analogue score (VAS),analgesic score mean score at month 6 numericla score,serum Cartilage Oligomeric Matric Protein. changes from baseline to 6 months ng/ml

—

Countries

Malaysia

Contacts

Public ContactAzidah Abdul Kadir

azidahkb@usm.my+60129286006

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026